Tango Therapeutics, Inc. — Cyborg Score 6/10

Strategic Profile

Tango leverages synthetic lethality and novel genetics-based approaches to develop medicines that take direct aim at specific tumors, including expanding into tumor suppressor gene loss and immune evasion mechanisms. The company's pipeline includes PRMT5 inhibitors for both CNS and non-CNS cancers, plus CoREST platform programs.

Cyborg Score Rationale

Early-stage biotech with validated synthetic lethality platform and advancing clinical pipeline, but pre-revenue from drug sales with negative EPS and modest market cap. Recent CEO transition and clinical-stage program dependencies present execution risks.

Top Insights

• Core platform uses synthetic lethality principle to develop precision cancer medicines targeting genetically defined patient populations
• Lead programs TNG462 and TNG456 are PRMT5 inhibitors in clinical development for pancreatic, lung, and brain cancers
• CoREST platform (TNG260) addresses immune evasion in STK11 loss-of-function mutations, expanding addressable market
• Recent CEO transition (Barbara Weber retiring, Malte Peters appointed) signals potential strategic repositioning

Named Competitors

• Precision Oncology Platform — DNA damage response inhibitors
• Homologous Recombination Repair — RAD51 inhibitors for precision oncology
• Precision Cancer Medicine — Targeted therapies for defined patient populations

Recent Developments

• (March 2026) CEO transition announced with Barbara Weber retiring and Malte Peters appointed successor
• (January 2026) Stock trading at $10.44 with market cap of $1.41B
• (September 2025) Trailing 12-month revenue of $66.5M with negative EPS of -$0.92

Open the full interactive Tango Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.